Although several molecules have been determined to be potential targets of anticancer therapy [5], sorafenib, which was designed to inhibit vascular endothelial growth factor (VEGF) signaling, is the only available agent with a clinically demonstrated antitumor effect on HCC [6,7]. Here, VEGFA is linked to hepatocellular carcinoma.